DETERMINING THE VALUE CONTRIBUTION OF TRIFLURIDINE/TIPIRACIL WITH BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN CATALONIA USING A MULTI-CRITERIA DECISION ANALYSIS

被引：0
|
作者：
Calle-Rodriguez, C. [1 ]
Elez, E. [2 ]
Manzano, J. L. [3 ]
Moreno-Martinez, M. E. [4 ]
Pericay, C. [5 ]
Graefenhain, R. [6 ]
Perez-Sadaba, F. [7 ]
Lizan, L. [7 ]
机构：
[1] Fundacio Sant Francesc dAssis, Barcelona, Spain
[2] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Barcelona, Spain
[3] Catalan Inst Oncol, Hosp Germans Trias Pujol, Barcelona, Spain
[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[5] Hosp Univ Mutua Terrassa, Barcelona, Spain
[6] Servier Espana, Madrid, Spain
[7] Outcomes10, Castellon de La Plana, Spain
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA26
引用
收藏
页码：S358 / S358
页数：1
相关论文
共 50 条
  • [1] Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
    Prager, Gerald W.
    Taieb, Julien
    Fakih, Marwan
    Ciardiello, Fortunato
    Van Cutsem, Eric
    Elez, Elena
    Cruz, Felipe M.
    Wyrwicz, Lucjan
    Stroyakovskiy, Daniil
    Papai, Zsuzsanna
    Poureau, Pierre-Guillaume
    Liposits, Gabor
    Cremolini, Chiara
    Bondarenko, Igor
    Modest, Dominik P.
    Benhadji, Karim A.
    Amellal, Nadia
    Leger, Catherine
    Vidot, Loick
    Tabernero, Josep
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (18): : 1657 - 1667
  • [2] Trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer
    Tasseau, Clara
    Gallois, Claire
    BULLETIN DU CANCER, 2024, 111 (12) : 1087 - 1088
  • [3] The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer
    Martinez-Perez, Julia
    Carmen Riesco-Martinez, M.
    Garcia-Carbonero, Rocio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (06) : 643 - 650
  • [4] Trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer treatment
    Michel, Patryk S.
    Jankowski, Marek
    Sigorski, Dawid
    Kubiatowski, Tomasz
    ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (06):
  • [5] Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment
    Hsu, Jason C.
    Lin, Jia-Yu
    Lin, Peng-Chan
    Lee, Yang-Cheng
    PLOS ONE, 2019, 14 (12):
  • [6] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: A retrospective study
    Li, Rongrong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Liu, Zhen-yang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
    Chida, Keigo
    Kotani, Daisuke
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Kuboki, Yasutoshi
    Shitara, Kohei
    Kojima, Takashi
    Taniguchi, Hiroya
    Watanabe, Jun
    Endo, Itaru
    Yoshino, Takayuki
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [8] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Kotani, Daisuke
    Kuboki, Yasutoshi
    Horasawa, Satoshi
    Kaneko, Asumi
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Bando, Hideaki
    Taniguchi, Hiroya
    Shitara, Kohei
    Kojima, Takashi
    Tsuji, Akihito
    Yoshino, Takayuki
    BMC CANCER, 2019, 19 (01)
  • [9] Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis
    de Moraes, Francisco Cezar Aquino
    Pessoa, Felipe Dirceu Dantas Leite
    Ribeiro, Caio Henrique Duarte de Castro
    Fernandes, Marianne Rodrigues
    Burbano, Rommel Mario Rodriguez
    dos Santos, Ney Pereira Carneiro
    BMC CANCER, 2024, 24 (01)
  • [10] Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
    Takahashi, Toshiaki
    Shigeyasu, Kunitoshi
    Kondo, Yoshitaka
    Takeda, Sho
    Umeda, Hibiki
    Moriwake, Kazuya
    Kayano, Masashi
    Sakurai, Yuya
    Nakamura, Shunsuke
    Takahashi, Masafumi
    Nitta, Kaori
    Yoshida, Kazuhiro
    Matsumi, Yuki
    Michiue, Hiroyuki
    Yamamoto, Hideki
    Kishimoto, Hiroyuki
    Teraishi, Fuminori
    Shoji, Ryohei
    Kanaya, Nobuhiko
    Kashima, Hajime
    Kakiuchi, Yoshihiko
    Kuroda, Shinji
    Kagawa, Shunsuke
    Fujiwara, Toshiyoshi
    BMC CANCER, 2025, 25 (01)
12345